In line with this possibility, recently, Hata et al. reported that the concomitant use of MEK and PI3K inhibitor lead to upregulation of PUMA and BIM, both of which were necessary for the induction of an apoptotic response in KRAS-mutant in another cancer type, non-small cell lung cancer (NSCLC) [31, 32]. Here, MAP2K7 is linked to non-small cell lung carcinoma.